- Home
- IOSP vs DNLI Comparison
IOSP vs DNLI Comparison
Compare IOSP & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOSP
- DNLI
- Stock Information
- Founded
- IOSP 1938
- DNLI 2013
- Country
- IOSP United States
- DNLI United States
- Employees
- IOSP N/A
- DNLI N/A
- Industry
- IOSP Major Chemicals
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IOSP Industrials
- DNLI Health Care
- Exchange
- IOSP Nasdaq
- DNLI Nasdaq
- Market Cap
- IOSP 2.2B
- DNLI 1.9B
- IPO Year
- IOSP 1998
- DNLI 2017
- Fundamental
- Price
- IOSP $84.73
- DNLI $13.21
- Analyst Decision
- IOSP Strong Buy
- DNLI Strong Buy
- Analyst Count
- IOSP 1
- DNLI 15
- Target Price
- IOSP $155.00
- DNLI $33.85
- AVG Volume (30 Days)
- IOSP 171.0K
- DNLI 1.3M
- Earning Date
- IOSP 05-08-2025
- DNLI 05-06-2025
- Dividend Yield
- IOSP 1.92%
- DNLI N/A
- EPS Growth
- IOSP N/A
- DNLI N/A
- EPS
- IOSP 1.08
- DNLI N/A
- Revenue
- IOSP $1,786,000,000.00
- DNLI N/A
- Revenue This Year
- IOSP $0.74
- DNLI N/A
- Revenue Next Year
- IOSP $7.75
- DNLI $256.73
- P/E Ratio
- IOSP $78.62
- DNLI N/A
- Revenue Growth
- IOSP N/A
- DNLI N/A
- 52 Week Low
- IOSP $80.32
- DNLI $10.57
- 52 Week High
- IOSP $133.53
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- IOSP 38.06
- DNLI 44.46
- Support Level
- IOSP $84.70
- DNLI $12.86
- Resistance Level
- IOSP $87.94
- DNLI $13.77
- Average True Range (ATR)
- IOSP 2.15
- DNLI 0.72
- MACD
- IOSP -0.26
- DNLI -0.08
- Stochastic Oscillator
- IOSP 8.91
- DNLI 32.29
About IOSP Innospec Inc.
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Fuel Specialties segment, which generates the majority of revenue, sells products used to improve fuel efficiency, boost engine performance, and reduce emissions for automobiles, boats, and airplanes. It also sells products used by oil field service providers in the extraction of oil and gas. The Performance Chemicals segment sells products to the personal-care industry. The Oilfield Services segment develops and markets products to prevent loss of mud.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.